BIOLOGICAL MODELING

Our vast tumor organoid repository enables new possibilities for therapy selection and drug discovery

We aim to transform therapy selection and drug discovery and development by building one of the world’s largest libraries of human ex vivo tumor-derived organoids that are characterized by molecular features and associated clinical outcomes in robust, reproducible 3D models.

Tempus 3D Tumor Organoid (TO) Screen

Accelerate your drug development with one of the industry’s most extensive collections of 3D patient-derived tumor organoids. These panels can help evaluate the efficacy of preclinical compounds, including small molecules, monoclonal antibodies (mAbs), and antibody-drug conjugates (ADCs), and can generate robust multimodal insights for your discovery and translational phase assets.

PanKRAS: 40 TOs featuring diverse KRAS mutations and wild-type controls, suitable for assets targeting the KRAS pathway
PanCRC: 40 colorectal cancer (CRC) TOs enriched for pre-treated models, suitable for assets intended as 2L/3L therapies

Space is limited—enroll by December 20, 2024 to secure your spot.

Enroll now

Lung cancer TO 3D morphology, with fluorescent staining of nuclei and cytoskeleton.

Our Solutions

Predefined organoid screening models

Predefined sets of organoid models enriched for specific characteristics (e.g., indication, biomarker, clinical data) can be used to screen test compounds and to test and generate hypotheses. Compounds can be screened alone and in combinations, providing a rapid and cost-effective alternative to in vivo preclinical animal experiments.

Learn more about our fixed panels

Custom organoid screening models

Client-selected organoids screened with or without allogeneic MHC-matched PBMCs, tailored to your research needs. A variety of compound classes can be screened across small molecules, mAbs, ADCs, cell engagers, and cellular therapies.

Tumor Origin: Pan-Cancer, client-selected indications
Molecular Profiling: Client-selected molecular alterations, mutations, CNVs, fusions, etc.

Single-cell RNA sequencing

Characterize cell populations of interest with precision–identify and validate complex signatures and identify biomarkers of therapeutic response

Spatial transcriptomics

Uncover spatio-temporal patterns of gene expression in two dimensions to better characterize the relationships between molecular profiles and therapeutic response

Case study

A large Biopharma collaborator used Tempus’ patient-derived organoids to unlock a critical investment decision. Read More

PAN-CANCER TUMOR ORGANOIDS

Breast
Colon
Endometrial Adeno
Gastric
Head + Neck SCC
Liver HCC
NSCLC Adeno
NSCLC SCC
Ovarian
Pancreatic

Our solutions can be broadly applied to preclinical and post-approval strategies

Biomarker and target validation
Indication selection
Exploratory (MOA) studies
Exploration of rare patient mutations and alterations
Combination identification and validation
RNA signature development for responder enrichment
Therapy resistant models to study disease biology
Immune cell activation
Label expansion plans

Our Differentiators

500+

commercially available biological models
Full characterization

of tumor organoids with Tempus xT solid tumor comprehensive profiling
Flexible

3D confocal imaging assays with AI analytics on every tumor organoid drug sensitivity screen
Innovative pipeline

of automation-driven assays enables expedited experimental processes
CAP-accredited, CLIA-certified

laboratories

How it works

Individual human ex vivo tumor-derived organoids are screened in Tempus’ high-throughput environment. Tempus organoids are NGS-characterized and have been pre-screened against a panel of chemotherapies and small molecule therapeutics. Our 3D models serve as the basis for drug screening efforts for drug discovery and development.

Organoids are grown in proprietary chemically defined conditions from core biopsies or surgical resections.
Organoid histology is verified by board-certified medical pathologists.
Full transcriptomic profiles are generated by RNA sequencing.
Tumor mutation recapitulation is assessed by overlap of somatic variants between tumor and tumor organoids via the Tempus xT & xR assays.
Organoids are phenotyped via high-content assays, which are then analyzed via automated machine vision algorithms employing state-of-the-art computer vision models to segment organoids, quantify infiltrating immune cells, and predict drug efficacies along with other clinical endpoints as desired.

Deep Learning-Enabled Dynamic Infiltration and Response to NK Therapies in Solid Tumor Organoids
Lonini et al. quantify immune cell infiltration across confocal microscopy images of tumor organoids (TOs) co-cultured with NK cells at increasing target-to-effector cell concentrations and find a high correlation between immune cell infiltration and TO death.
READ PUBLICATION
Integration of Patient-Derived Tumor Organoids and Patient Clinical Multimodal Data To Investigate the Role of Organoids in Predicting Treatment Response
Burke et al. sequence and analyze 38 patient-derived organoids (PDOs) with paired patient clinical data across nine different cancer types, indicating a correlation between treatment responses in PDOs and patients' responses to corresponding drugs, thus highlighting the valuable role of PDOs in predicting patient treatment outcomes.
READ PUBLICATION
Detecting HLA Loss of Heterozygosity Within a Standard Diagnostic Sequencing Workflow for Prognostic and Therapeutic Opportunities
Lozac’hmeur et al. Develop and validate an investigational assay that detects tumor HLA loss of heterozygosity (LOH) within an FDA-approved clinical diagnostic test, enabling the use of HLA LOH in diagnostic, prognostic, and therapeutic applications.
READ PUBLICATION

Partnering with Tempus is investing in the future

We’ve created a biological modeling infrastructure centered on ex vivo tumor organoids to help you accelerate your research needs.